Christopher R. Flowers, MD, on Disparities in Lymphoma and Myeloma

Article

The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.

In an interview with CancerNetwork®, Christopher R. Flowers, MD, department chair for the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, discussed the existing disparities in lymphoma and myeloma outcomes among minority and rural patients, as well as various ways to increase minority enrollment in clinical trials to address the disparities. 

According to Flowers, these disparities have been identified by race in lymphoma in terms of the age of onset, with African Americans presenting at a younger age. Moreover, there are disparities in outcome where there are differences in survival by both race and insurance status, with patients who are uninsured or who have Medicaid insurance generally having worse outcomes. Even further, there are disparities by rural status where they have found that individuals who come from a rural or urban area have worse survival compared to those who live in metropolitan areas. 

“There are very clear differences in outcomes for patients in those groups, and those are the kinds of populations that we would like to target in ways that improve those outcomes,” said Flowers. 

Flowers indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials. For instance, looking at new approaches for care, new strategies or algorithms for traditional care practices, or even new therapies in some situations could be beneficial. 

“I’m hopeful that we’re in a brand new era where there are opportunities to make marked in roads,” Flowers said.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences National Broadcast, airing daily on all MJH Life Sciences channels.

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
4 experts are featured in this series.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
3 experts in this video
3 experts in this video
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content